#Pharmaceutical Analytical Testing Outsourcing Market

[industrynewsupdates]

Pharmaceutical Analytical Testing Outsourcing Market 2024-2030: Trends and Opportunities

The global pharmaceutical analytical testing outsourcing market size was valued at USD 8.3 billion in 2023 and is projected to grow at a CAGR of 8.4% from 2024 to 2030.

Growth in the market can be attributed due to increasing focus toward safety, & quality; regulation, pricing benefits of outsourcing, and rising number of end use. Besides, increasing R&D investment is one of the critical sustainability strategies adopted by market players. As, not all companies have an infrastructure for analytical testing. Therefore, outsourcing these operations is a suitable option, which helps to save time and cost.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Analytical Testing Outsourcing Market 

Other factors, such as the changing regulations for in vivo and in vitro tests, are also expected to propel the growth of the market for pharmaceutical analytical testing outsourcing. Besides, high demand for quality generic drugs, analytical testing methods, improved the quality and transparency of the review & approval process, and encourage new drug R&D in line with global development is anticipated to fuel the market growth.

In addition, innovation or new product development is directly proportional to the demand for testing services due to pricing concerns, competitive pressures, and lead-time to market, companies are opting for outsourcing of testing services. Moreover, focus on customized care and technological advancements, which has resulted in rapid development of new products. Likewise, development of biosimilar, combination products, and other innovative medicines has fueled the demand for pharmaceutical analytical testing services.  

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global pharmaceutical regulatory affairs market size was estimated at USD 8.84 billion in 2023 and is projected to grow at a CAGR of 7.16% from 2024 to 2030. 

• The global pharmaceutical packaging market size was valued at USD 139.37 billion in 2023 and is expected to grow a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030.

Pharmaceutical Analytical Testing Outsourcing Market Segmentation

Grand View Research has segmented the prebiotic ingredient market based on type, application, and region:

Type Outlook (Revenue, USD Million, 2017 - 2028)

• Inulin

• Oligosaccharide (MOS/GOS/FOS)

• Others

Applications Outlook (Revenue, USD Million, 2017 - 2028)

• Food & Beverage

• Dietary Supplements

• Others

Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America

• Europe

• Asia Pacific

• Central & South America

• Middle East & Africa

Key Companies & Market Share Insights

Companies' are focusing on innovating new types of prebiotic ingredients to meet the increasing demand. New players are entering the market owing to low market entry barriers and higher market potential. The increasing demand for prebiotic ingredients offers an opportunity for product development in the regions of high demand. Some of the prominent players in the global prebiotic ingredient market include:

• Beneo-Orafti SA

• Tereos Group

• Ingredion Inc.

• Cargill Inc.

• DowDuPont Inc

• Royal FrieslandCampina N.V.

• Kerry Group

• Cosucra-groupe Warcoing SA

• Sensus BV

Recent Developments

• In December 2023, Agno Pharma acquired Lubrizol Particle Sciences Inc. The acquisition encompasses the drug product formulation technology integral to Particle Sciences Inc. including the PA, Bethlehem development & manufacturing site.

• In November 2023, Eurofins acquired Quasfar supporting the pharmaceutical industry in Latin America, enhancing its capabilities in R&D, providing support in the early stages of pharmaceutical product development.

Order a free sample PDF of the Pharmaceutical Analytical Testing Outsourcing Market Intelligence Study, published by Grand View Research. 

[blog-site-for-market-research]

Market Report: Delving into the Pharmaceutical Analytical Testing Outsourcing Market Size and Share

Market Overview –

The Pharmaceutical Analytical Testing Outsourcing Market refers to the sector within the pharmaceutical industry where companies outsource their analytical testing needs to specialized service providers. This market has witnessed significant growth in recent years due to the increasing complexity of drug formulations and the stringent regulatory requirements imposed by health authorities worldwide.

Outsourcing Analytical Testing in the pharmaceutical industry is witnessing significant traction as companies seek cost-effective and specialized solutions. Outsourcing firms offer expertise in analytical testing, ensuring regulatory compliance and quality assurance. This trend is driven by the complexity of testing requirements and the need for efficient resource allocation. The market for outsourcing analytical testing services is expected to continue growing as pharmaceutical companies prioritize core activities and seek external expertise.

Companies outsource analytical testing to gain access to state-of-the-art facilities, expertise, and specialized technologies without the need for heavy investments in infrastructure and personnel training. This trend is particularly pronounced among smaller pharmaceutical companies and startups with limited resources.

Key players in the Pharmaceutical Analytical Testing Outsourcing Market include contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and independent analytical laboratories. These entities offer a wide range of services, including method development and validation, stability testing, raw material testing, and quality control testing.

Factors driving the growth of this market include the increasing globalization of the pharmaceutical industry, the rising demand for specialized analytical techniques such as mass spectrometry and chromatography, and the growing emphasis on outsourcing non-core activities to focus on core competencies.

Despite the opportunities, the market faces challenges such as data security concerns, quality control issues, and the need for regulatory compliance. However, with the right strategies in place, the Pharmaceutical Analytical Testing Outsourcing Market is poised for continued growth and innovation in the coming years.

In 2022, the pharmaceutical analytical testing outsourcing market was estimated to be worth USD 4.2 billion. According to projections, the pharmaceutical analytical testing outsourcing market is expected to increase at a compound annual growth rate (CAGR) of 8.70% from USD 4.6 billion in 2023 to USD 7.5 billion by 2030.

Segmentation –

The global pharmaceutical analytical testing outsourcing market, by product type, has been segmented into finished products, active pharmaceutical ingredients, and raw materials. The finished products segment accounted for a value of USD 2,055.4 million in 2017. The market, by services, can be segmented into bioanalytical testing, method development & validation, stability testing, and others. On the basis of end user, the global pharmaceutical analytical testing outsourcing market is segmented into pharmaceutical & biopharmaceutical companies and biotechnology industry.

Regional Analysis –

The Pharmaceutical Analytical Testing Outsourcing Market exhibits diverse regional trends influenced by factors such as regulatory frameworks, technological advancements, and the presence of outsourcing service providers.

North America dominates the market, driven by stringent regulatory requirements, a robust pharmaceutical industry, and a high demand for outsourcing services to ensure compliance and product quality. The region also benefits from a mature outsourcing ecosystem and a strong network of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Similarly, Europe holds a significant market share, supported by a well-established pharmaceutical sector, favorable regulatory environment, and increasing emphasis on cost-effective solutions.

In Asia Pacific, the market is witnessing rapid growth fueled by the outsourcing trend among pharmaceutical companies, expanding healthcare infrastructure, and a skilled workforce at competitive costs. Latin America and the Middle East & Africa regions present opportunities for market expansion, driven by the growing pharmaceutical industry, improving regulatory landscape, and cost advantages. However, challenges such as quality control issues and intellectual property concerns may impact market growth in these regions. Overall, the Pharmaceutical Analytical Testing Outsourcing Market showcases a dynamic landscape across different regions, characterized by varying regulatory environments, outsourcing capabilities, and market demands.

Key Players –

Pharmaceutical analytical testing outsourcing companies include Boston Analytical (New Hampshire), West Pharmaceutical Services, Inc. (U.S.), Exova Group PLC (U.K.), Source BioScience (U.K.), Pace Analytical Services, Inc. (U.S.), Merck KGaA (Germany), WuXi AppTec (U.S.), Toxikon (U.S.), Eurofins Scientific (Belgium and Luxembourg), Intertek Group Plc (U.K.), Charles River Laboratories International, Inc (U.S.), SGS SA (U.K.), and Pharmaceutical Product Development, LLC (U.S.).

Related Reports –

Neurostimulation Devices

Crohn’s Disease

Healthcare Biometrics

Osteoporosis Drugs

For more information visit at MarketResearchFuture

[marketreports-blog]

The U.S. pharmaceutical analytical testing outsourcing market size was exhibited at USD 4.50 billion in 2023 and is projected to hit around USD 9.07 billion by 2032, growing at a CAGR of 8.1% during the forecast period 2023 to 2032.

[luckydige45]

The U.S. pharmaceutical analytical testing outsourcing market size was exhibited at USD 4.50 billion in 2023 and is projected to hit around USD 9.07 billion by 2032, growing at a CAGR of 8.1% during the forecast period 2023 to 2032.

[hariganesh858]

Whole Exome Sequencing Market

Whole Exome Sequencing Market Size, Share, Trends: Illumina, Inc. Leads

Growing adoption of WES in clinical diagnostics

Market Overview: 

The global Whole Exome Sequencing Market is projected to grow at a CAGR of 15.5% during the forecast period from 2024 to 2031. North America dominates this market, accounting for approximately 40% of the global market share. Key metrics include the increasing adoption of WES in clinical diagnostics, growing demand for personalized medicine, and advancements in sequencing technologies.

The whole exome sequencing industry is expanding rapidly, driven by lower sequencing costs, an increase in the incidence of genetic disorders, and the increased use of WES in drug discovery and development. The combination of WES with artificial intelligence and big data analytics is driving market growth by allowing for the discovery of novel disease-causing genes and the creation of tailored treatments.

DOWNLOAD FREE SAMPLE

Market Trends: 

The whole exome sequencing market is shifting significantly towards clinical applications, particularly in the diagnosis of uncommon genetic disorders and cancer. WES allows for the quick and cost-effective discovery of disease-causing variants in the genome's protein-coding regions, which account for roughly 85% of all known disease-causing mutations.

According to recent industry viewpoints, the number of clinical WES tests performed has increased by 40% in the last three years, owing to the increased availability of WES services in clinical laboratories and the growing awareness of WES as a viable diagnostic tool. Industry analysts believe that by 2030, WES will be used as a routine diagnostic test for individuals with suspected genetic diseases, replacing traditional gene-by-gene testing methods.

Market Segmentation: 

The services segment dominates the whole exome sequencing market, accounting for over 50% of the market share. WES services, which include sample preparation, sequencing, and data analysis, have emerged as the dominant segment in the exome sequencing market. The increased demand for outsourced WES services from research institutes, pharmaceutical corporations, and clinical laboratories is propelling the expansion of this sector.

According to our analysis, revenue from WES services has expanded at a 25% annual rate over the last five years, exceeding growth in the product segment. The growing complexity of WES workflows, as well as the requirement for specialised knowledge in data analysis, are boosting demand for WES services, especially among smaller research groups and clinical laboratories.

Market Key Players:

Illumina, Inc.

Thermo Fisher Scientific, Inc.

Agilent Technologies, Inc.

Hoffmann-La Roche Ltd.

Qiagen N.V.

Beijing Genomics Institute (BGI)

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[health-views-updates]

Future Trends in Host Cell Protein Testing Market: Size, Demand & Growth 2024-2032

Host Cell Protein Testing Market: Unlocking New Opportunities in Biopharmaceutical Advancements

The Host Cell Protein Testing Market Revenue is witnessing unprecedented growth, driven by the increasing demand for biologics and the stringent regulatory guidelines for biopharmaceutical manufacturing. Host Cell Protein (HCP) testing plays a crucial role in ensuring the safety, efficacy, and quality of biologic products by detecting and quantifying residual host cell proteins that may be present after the purification of therapeutic proteins or monoclonal antibodies. This growing focus on advanced therapeutic modalities and compliance has significantly expanded the market's scope globally.

According to a recent report published by SNS Insider, the Host Cell Protein Testing Market is poised to experience robust growth, attributed to technological advancements in testing methods, rising investment in biologics production, and increasing reliance on outsourced testing services. With the biopharmaceutical industry evolving rapidly, HCP testing is emerging as a critical factor in safeguarding patient safety while meeting rigorous global regulatory standards.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/2623

Driving Factors and Market Dynamics

The biopharmaceutical industry's continuous growth has elevated the importance of stringent quality control processes, and HCP testing is central to this paradigm. Key drivers influencing the market include:

Expanding Biologics Market: The surge in demand for biologics, such as monoclonal antibodies, vaccines, and cell/gene therapies, necessitates precise HCP testing. These therapies are highly sensitive to contamination, making rigorous testing indispensable.

Technological Innovations: Advances in testing methodologies, such as ELISA (enzyme-linked immunosorbent assay) and mass spectrometry, are enhancing the accuracy, speed, and reliability of HCP detection.

Outsourcing Trends: Many pharmaceutical and biotech companies are outsourcing their HCP testing needs to specialized service providers, driving the demand for dedicated testing laboratories and CROs (contract research organizations).

Moreover, the regulatory landscape is becoming increasingly stringent, with agencies like the FDA and EMA mandating robust HCP testing protocols to ensure therapeutic safety. This has further augmented the need for standardized testing platforms and services worldwide.

Regional Insights

North America continues to dominate the Host Cell Protein Testing Market, owing to its strong biopharmaceutical manufacturing base, robust R&D activities, and well-established regulatory framework. Meanwhile, the Asia-Pacific region is emerging as a high-growth market due to increasing investments in biopharmaceutical infrastructure, cost-effective manufacturing capabilities, and expanding healthcare access.

Challenges and Opportunities

While the market is on a growth trajectory, challenges such as high costs associated with advanced testing equipment, the complexity of HCP analysis, and a lack of standardization in emerging economies may hinder growth. However, these challenges also present opportunities for innovation in cost-effective testing solutions and collaboration between regulatory bodies and industry stakeholders to establish uniform guidelines.

Future Outlook

The Host Cell Protein Testing Market is expected to witness accelerated growth as biopharmaceutical companies continue to focus on quality, innovation, and compliance. Emerging technologies such as AI-driven analytics and automation are likely to play a pivotal role in shaping the future of HCP testing, offering enhanced precision and efficiency.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us: Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[lanettcdmo]

Pharma Contract Manufacturing Services: A Guide to Streamlining Production and Ensuring Quality

 In today’s competitive pharmaceutical landscape, companies are increasingly turning to contract manufacturing services to streamline production, maintain quality, and reduce costs. Pharma contract manufacturing services enable pharmaceutical companies to focus on core competencies—like research and development—while outsourcing the complex manufacturing process to experienced partners. In this blog, we’ll explore the benefits, types, and key considerations of pharma contract manufacturing services.

What Are Pharma Contract Manufacturing Services?

Pharma contract manufacturing involves outsourcing part or all of a company’s drug production processes to a third-party manufacturer. These services cover a wide range of production needs, including:

API (Active Pharmaceutical Ingredient) Manufacturing: Producing high-quality ingredients essential for drug efficacy.

Finished Dosage Form Manufacturing: Manufacturing drugs in final forms like tablets, capsules, injectables, and topical formulations.

Packaging and Labeling: Ensuring that the packaging meets both regulatory standards and marketing requirements.

Quality Control and Compliance: Conducting rigorous testing to maintain product safety, quality, and regulatory compliance.

By partnering with a contract manufacturer, pharmaceutical companies can ensure their products are produced to the highest standards without the need for an extensive in-house manufacturing infrastructure.

The Importance of Pharma Contract Manufacturing Services

The pharmaceutical industry is governed by strict regulations and quality standards, requiring advanced equipment, specialized facilities, and extensive quality control measures. Pharma contract manufacturing services are crucial for several reasons:

Cost Efficiency Building and maintaining manufacturing facilities requires significant capital investment and ongoing operational expenses. Contract manufacturers already have the necessary infrastructure and expertise, enabling pharmaceutical companies to reduce costs and allocate resources more efficiently.

Scalability and Flexibility Demand in the pharmaceutical market can be unpredictable, particularly with new product launches or seasonal drugs. Contract manufacturers offer scalability, allowing companies to ramp up or reduce production based on demand without heavy fixed costs.

Speed to Market Bringing a drug to market quickly can be crucial for both patient needs and profitability. By partnering with an experienced contract manufacturer, companies can significantly shorten production timelines and gain a competitive advantage.

Access to Expertise and Advanced Technology Contract manufacturers specialize in pharmaceutical production, providing access to highly trained professionals, state-of-the-art equipment, and advanced technologies. This expertise allows for better quality and improved efficiency across all stages of drug production.

Types of Pharma Contract Manufacturing Services

Pharmaceutical companies can select from various contract manufacturing services based on their specific needs:

Full-Service Manufacturing: From API production to final packaging, full-service manufacturers handle the entire production lifecycle.

API Manufacturing: Some companies outsource only the production of active pharmaceutical ingredients, relying on the manufacturer’s expertise to create high-quality, compliant ingredients.

Formulation and Development: In addition to production, some manufacturers assist with developing stable formulations that enhance drug efficacy and patient experience.

Analytical and Quality Control Services: Many contract manufacturers provide robust quality control and testing services, ensuring compliance with global regulatory standards.

Packaging and Labeling: Compliance with packaging regulations is essential, and some contract manufacturers specialize in offering tailored packaging solutions that meet both regulatory and brand requirements.

How to Choose the Right Pharma Contract Manufacturer

Selecting the right pharma contract manufacturer is crucial for ensuring product quality, safety, and compliance. Here are some factors to consider when choosing a partner:

Experience and Industry Expertise Look for a contract manufacturer with experience in your specific therapeutic area or product type. Their expertise will help ensure efficient production and compliance with industry standards.

Regulatory Compliance and Certifications Verify that the manufacturer complies with relevant standards, such as GMP (Good Manufacturing Practice) and has the necessary certifications, including FDA, ISO, and EMA. This compliance is essential for meeting international regulatory requirements.

Quality Control and Testing Capabilities Quality control is critical in pharma manufacturing. Make sure the contract manufacturer has rigorous testing protocols, advanced laboratory facilities, and well-documented quality assurance practices.

Scalability and Flexibility Assess whether the manufacturer can accommodate your production needs as they grow. A good contract manufacturer will offer scalability, allowing you to increase production as demand rises.

Communication and Transparency A successful partnership requires clear communication and transparency. Look for a contract manufacturer who values open communication and provides regular updates, enabling effective collaboration and accountability.

Trends in Pharma Contract Manufacturing

The pharma contract manufacturing industry is constantly evolving. Here are some trends that are shaping the industry:

Growth in Biologics Manufacturing With the rising demand for biologics—such as monoclonal antibodies and cell therapies—many contract manufacturers are investing in specialized facilities and expertise.

Sustainability and Eco-Friendly Practices As environmental concerns grow, many contract manufacturers are implementing eco-friendly practices, such as green chemistry and sustainable waste management, to reduce their environmental impact.

Increased Use of Digital Technologies Digital transformation is reshaping the pharmaceutical industry. Advanced technologies, such as AI, automation, and data analytics, are increasingly being used in manufacturing to improve efficiency, quality, and speed.

Conclusion

Pharma contract manufacturing services are an invaluable asset for pharmaceutical companies looking to streamline production, reduce costs, and ensure quality. By choosing the right partner, companies can focus on their core strengths—such as R&D and marketing—while relying on experienced manufacturers to handle production.

Whether you’re a growing biotech startup or a global pharma leader, outsourcing to a contract manufacturer could be the key to improving efficiency, reducing risk, and achieving faster time-to-market. Contact us today to explore how our contract manufacturing services can support your business needs and help you bring quality pharmaceuticals to the market more efficiently.

[medicinemanufacturing]

Understanding the Role of CDMO Pharma Companies in the Drug Development Lifecycle

CDMO pharma companies are critical in accelerating drug development in today's pharmaceutical world. These Contract Development and Manufacturing Organizations (CDMOs) provide specialised services to pharmaceutical companies, ranging from early research and development to manufacturing and packaging, allowing businesses to bring life-saving pharmaceuticals to market more efficiently. CDMOs, with their experience in formulation, testing, and manufacturing, are critical industry partners who assist innovation while ensuring product safety and quality. 

Key Services Provided by CDMO Pharma Companies

A CDMO provides services throughout the drug development process. By collaborating with a CDMO, pharmaceutical businesses receive access to a broad spectrum of solutions, each geared to meet tight regulatory criteria and optimise product quality:

Formulation and Development: One of CDMOs' primary capabilities is drug formulation. CDMOs collaborate with pharmaceutical companies to create formulations that optimise a drug's stability, bioavailability, and effectiveness. A well-established CDMO can manage the special requirements of each formulation, whether oral, injectable, or topical.

Analytical Testing and Validation: Thorough testing is required to meet safety and regulatory requirements. CDMOs conduct extensive analytical testing to ensure a drug's purity, potency, and safety. This involves stability testing, technique validation, and FDA and regulatory criteria adherence. CDMOs use advanced laboratory facilities to verify that all drug formulations fulfil industry and market standards.

Clinical Trial Manufacturing: CDMOs supply clinical trial materials to support various study phases before full-scale production. From tiny batches for the Phase I study to larger volumes for Phase III, CDMOs help with the manufacturing process and provide experience in documentation, labelling, and shipping. This enables pharmaceutical businesses to maintain the quality and compliance required at each trial stage.

Commercial manufacture and Packaging: After a medicine is approved, CDMOs conduct large-scale manufacture to enable a smooth transition from clinical trials to commercial distribution. They also provide regulatory-compliant packaging services, ensuring each product is appropriately labelled and transported safely. CDMOs use innovative technologies to maximise production while maintaining strict quality control throughout the manufacturing and packaging.

Benefits of Partnering with a CDMO

Partnering with a CDMO provides pharmaceutical businesses with various benefits, including:

Faster Time-to-Market: CDMOs shorten the time it takes to bring a novel medicine to market by leveraging their established facilities, resources, and experience. Their skills enable speedier formulation, testing, and scaling, ensuring that life-saving drugs reach patients sooner.

Cost-effectiveness: CDMOs eliminate the need for pharmaceutical companies to invest in their production facilities, personnel, and equipment, which can be costly and time-consuming. Companies that outsource to a CDMO save money on capital and better manage their costs.

Access to Specialized Expertise: CDMOs employ highly skilled scientists, researchers, and technicians knowledgeable about regulatory standards and best practices. This knowledge is beneficial for navigating complex processes and maintaining compliance with strict requirements.

CDMO pharma companies are crucial partners throughout the drug development lifecycle, helping everything from preliminary research to commercial production. Their knowledge assists pharmaceutical businesses in navigating regulatory difficulties, reducing costs, and delivering high-quality pharmaceuticals to the market effectively. Companies who work with a reputable CDMO, such as Prakruti Life Sciences, get an ally dedicated to guiding them through the road from concept to market-ready product, ensuring quality at every level.

[communicationblogs]

Failure Analysis Market — Forecast(2024–2030)

Overview

As the technology is evolving the tools for identifying and correction of failure has becoming easy and increase in usage of technology is driving the failure testing market With the complexity of electronic devices and materials continuously increasing, there’s a growing demand for more advanced analytical techniques in failure analysis. This includes techniques such as scanning electron microscopy (SEM), transmission electron microscopy (TEM), focused ion beam (FIB) microscopy, X-ray imaging, and spectroscopy. These techniques enable finer resolution, deeper analysis, and greater accuracy in identifying failure modes, thereby driving the adoption of sophisticated failure analysis solutions. Many companies are increasingly outsourcing their failure analysis needs to specialized service providers. Outsourcing offers several advantages, including access to expertise and equipment not available in-house, faster turnaround times, and cost savings. Additionally, as failure analysis becomes more specialized and requires highly skilled personnel and expensive equipment, outsourcing provides a more efficient and cost-effective solution for many organizations. As a result, the market for failure analysis services is witnessing significant growth, with specialized firms catering to a wide range of industries and applications.

These trends reflect the evolving needs and challenges in failure analysis and are driving innovation and growth in the market. However, it’s essential to consult more recent sources to confirm if these trends persist or if there have been new developments since my last update.

Request Sample

The report: “Failure Analysis Market — Forecast (2024–2030)”, by IndustryARC, covers an in-depth analysis of the following segments of the Barium Sulphate Industry. Market.

By Product: Transmission Electron Microscope, Focused Ion Beam Systems, Scanning Electron Microscopy, Dual Beam Systems, Others

By Test: Fractography, Metallography, Mechanical Testing, Chemical Analysis and Testing, NDT, Weld Testing, Microstructure Evaluation, Adhesive Identification, Coating

Contamination, Thermal Mapping, Electrical Overstress (EOS)/Electrostatic Discharge (EDS), Regulatory Compliance Testing, Others

By Techniques: Fault Tree Analysis (FTA), Common-Mode Failure Analysis, Failure Modes Effect Analysis (FMEA), Failure Modes, Effects and Criticality Analysis (FMECA), Functional Failure Analysis, Sneak Circuit Analysis, Software Failure Analysis, Others

By Technology: Broad ion milling, Focused ion milling, Relative ion etching, Secondary ion mass spectroscopy, Energy dispersive X-Ray Spectroscopy

By Application: Bio Science Cellular Biology, Neuroscience, Bio Medical, Others. Electronics: Semiconductors, Others. Renewable Energy: Solar, Wind. Agriculture: Machinery & Tools. Oil and Gas, Machinery & Tools. Commercial Aerospace.

Defense: Marine, Aerospace, Ground. Automotive: Automotive Materials Testing, Automotive Plastics and Polymers Physical Testing, Automotive Exterior Testing and Expertise, Automotive Interior Testing and Expertise. Construction. Chemical and Pharmaceutical. Healthcare Equipment. Food & Beverage. Mining. Polymer. Paper & Fiber material. Ceramic & Glass. Nanofabrication. Others.

By Geography: By Geography: North America (US, Canada and Mexico), Europe (UK, France, Germany, Italy, Spain, Russia, Netherlands, Belgium, and Rest of Europe), APAC (China, Japan, India, South Korea, Australia and New Zealand, Indonesia, Taiwan, Malaysia and Rest of APAC), South America (Brazil, Argentina, Colombia, Chile, Rest of South America), and RoW (Middle East and Africa).

Inquiry Before Buying

Key Takeaways

• Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level — for product types, end use applications and by different industry verticals.

• Understand the different dynamics influencing the market — key driving factors, challenges and hidden opportunities.

• Get in-depth insights on your competitor performance — market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.

• Analyze the sales and distribution channels across key geographies to improve top-line revenues.

• Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.

• Get a quick outlook on the market entropy — M&A’s, deals, partnerships, product launches of all key players for the past 4 years.

• Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.

Failure Analysis Market Segment Analysis — By Application

The automotive sector has seen notable technological advancements such as Advanced Driver Assistance Systems (ADAS), connected vehicles, Internet of Things (IoT) devices, and smart sensors. These innovations play a crucial role in preventing potential accidents caused by malfunctions in critical vehicle components. According to a June 2022 report from the World Health Organization (WHO), around 1.3 million lives are lost annually due to road traffic accidents, with 20 to 50 million individuals sustaining non-fatal injuries Potential causes of automotive device failures include aspects like product design, manufacturing processes, material source contamination, product packaging, mishandling, and incorrect calibration. These factors underscore concerns about the manufacturing quality of automotive parts and the necessity for proactive measures to mitigate incidents.The Asia-Pacific region has experienced significant growth in the automotive sector, fueled by increasing demand for both passenger and advanced vehicles. The region’s high population density contributes to elevated usage of passenger vehicles, thus driving market expansion. In 2022, China’s automotive industry alone produced approximately 23.8 million passenger cars, as reported by the International Organization of Motor Vehicle Manufacturers (OICA).

Failure Analysis Market Segment Analysis — Electronics & Semiconductor

The dominance of the electronics and semiconductor application segment in the failure analysis market is evident, holding the largest share. This is primarily attributed to the escalating demand for miniature transistor chips, Nano electronics, and optoelectronics across various industries. The electronics and semiconductor sector is emerging as a pivotal player, fueled by the rising adoption of robotics and automation in the manufacturing of electronic devices. This surge in automation has led to a requirement for high-density, integrated, and miniaturized devices to facilitate the production of smart devices, wearables, and intelligent industrial equipment. As a result, the need for robust failure analysis solutions within this sector has become increasingly pronounced, driving the dominance of the electronics and semiconductor segment in the market.

Failure Analysis Market Segment Analysis — Geography

During the projected period, the Asia Pacific region is expected to demonstrate the highest Market Share of 45 % The significant mass production of electronic goods such as smartphones, tablets, sensors, industrial equipment, wearables, and white goods in China and Taiwan is set to propel the expansion of the failure analysis market in this area. Japan holds a prominent position as the primary market for microscopy equipment in the Asia Pacific region. Major industry players like Nikon, JEOL Ltd., Olympus, and Hitachi High-Technologies are headquartered in Japan, enjoying strong patronage from major research institutions, pharmaceutical companies, and biotechnology firms. In China, the manufacturing sector is actively embracing industrial robots to automate and modernize various manufacturing processes. This transition has created a demand for monitoring device failures, presenting fresh growth prospects for the failure analysis market in the country.

Failure Analysis Market Share (%) By Region, 2023

Buy Now

Drivers — Failure Analysis Market

Fusion of Microscopy and Spectroscopy

The integration of microscopy with spectroscopy is poised to unlock significant opportunities across research communities, offering a wide array of applications. For instance, merging Raman spectroscopy with either atomic force microscopy or optical microscopy provides intricate insights into nanoscale properties and composition. The combined techniques synergize to facilitate precise sample alignment, efficient optical signal transfer from microscope to spectrometer, and accurate focusing of excitation light at the detection point.The potential of amalgamating microscopy technologies has led to innovations like the DXR2 Raman Imaging Microscope by Thermo Fisher Scientific. This instrument seamlessly integrates an optical microscope with a Raman spectrometer, allowing for the acquisition of both traditional optical and petrochemical images

Challenges — Failure Analysis Market

Elevated Ownership and Maintenance Expenses

There has been a noticeable shift in microscopy usage trends, with traditional models gradually being replaced by high-end alternatives such as electron microscopes, scanning probe microscopes, and digital microscopes. This transition is fueled by the advanced features, superior resolution, and magnification capabilities offered by these modern instruments. However, a significant barrier to their widespread adoption lies in their high cost, which can range from USD 25,000 to USD 2 million. This pricing hurdle limits their accessibility in settings like hospitals, pathological laboratories, and small-scale industries. Furthermore, the ongoing expenses associated with microscope maintenance add to the overall ownership costs. For instance, maintenance costs for a transmission electron microscope can fall within the range of USD 15,000 to USD 100,000 per year. These steep expenses often necessitate heavy reliance on government and private research funding, consequently restraining market growth to a certain extent.

Market Landscape

Failure Analysis Market Segment Analysis Market Landscape

Technology launches, acquisitions and R&D activities are key strategies adopted by players in the Window Films Market. Major players in the Failure Analysis Market are

Hitachi High-Tech, Intertek, JEOL, Motion X, TESCAN, ZEISS, A&D Company, Carl Zeiss SMT, FEI, Thermo Fisher Scientific and Others.

[blog-site-for-market-research]

Navigating the Dynamics of Pharmaceutical Analytical Testing Outsourcing Market Industry

Market Overview –

The Pharmaceutical Analytical Testing Outsourcing Market is experiencing robust growth as pharmaceutical companies increasingly outsource their analytical testing needs to specialized service providers. Analytical testing is crucial in the pharmaceutical industry for ensuring the safety, quality, and efficacy of drug products.

Outsourcing Analytical Testing in the pharmaceutical industry is witnessing significant traction as companies seek cost-effective and specialized solutions. Outsourcing firms offer expertise in analytical testing, ensuring regulatory compliance and quality assurance. This trend is driven by the complexity of testing requirements and the need for efficient resource allocation. The market for outsourcing analytical testing services is expected to continue growing as pharmaceutical companies prioritize core activities and seek external expertise.

The market is driven by several factors, including the growing complexity of drug formulations, stringent regulatory requirements, and the need for specialized expertise and equipment. Outsourcing analytical testing allows pharmaceutical companies to access state-of-the-art facilities and specialized skills without making significant investments in infrastructure and personnel.

Moreover, outsourcing offers flexibility, scalability, and cost-effectiveness, enabling companies to streamline their operations and focus on core activities such as drug discovery and development. As a result, outsourcing analytical testing has become a strategic imperative for many pharmaceutical companies, driving the growth of the market.

Key players in the market range from contract research organizations (CROs) to specialized analytical testing laboratories, offering a wide range of services, including method development, validation, stability testing, and quality control.

The pharmaceutical analytical testing outsourcing market is also witnessing increasing demand from emerging markets, where pharmaceutical companies seek to leverage cost advantages and access local expertise. Additionally, the COVID-19 pandemic has further accelerated the adoption of outsourcing as companies strive to meet growing demand for testing services while managing disruptions to their operations.

Overall, the pharmaceutical analytical testing outsourcing market is expected to continue its expansion, driven by the growing demand for high-quality analytical services, regulatory compliance, and operational efficiency within the pharmaceutical industry.

In 2022, the pharmaceutical analytical testing outsourcing market was estimated to be worth USD 4.2 billion. According to projections, the pharmaceutical analytical testing outsourcing market is expected to increase at a compound annual growth rate (CAGR) of 8.70% from USD 4.6 billion in 2023 to USD 7.5 billion by 2030.

Segmentation –

The global pharmaceutical analytical testing outsourcing market, by product type, has been segmented into finished products, active pharmaceutical ingredients, and raw materials. The finished products segment accounted for a value of USD 2,055.4 million in 2017. The market, by services, can be segmented into bioanalytical testing, method development & validation, stability testing, and others. On the basis of end user, the global pharmaceutical analytical testing outsourcing market is segmented into pharmaceutical & biopharmaceutical companies and biotechnology industry.

Regional Analysis –

The Pharmaceutical Analytical Testing Outsourcing Market exhibits diverse regional trends influenced by factors such as regulatory frameworks, technological advancements, and the presence of outsourcing service providers.

North America dominates the market, driven by stringent regulatory requirements, a robust pharmaceutical industry, and a high demand for outsourcing services to ensure compliance and product quality. The region also benefits from a mature outsourcing ecosystem and a strong network of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Similarly, Europe holds a significant market share, supported by a well-established pharmaceutical sector, favorable regulatory environment, and increasing emphasis on cost-effective solutions.

In Asia Pacific, the market is witnessing rapid growth fueled by the outsourcing trend among pharmaceutical companies, expanding healthcare infrastructure, and a skilled workforce at competitive costs. Latin America and the Middle East & Africa regions present opportunities for market expansion, driven by the growing pharmaceutical industry, improving regulatory landscape, and cost advantages. However, challenges such as quality control issues and intellectual property concerns may impact market growth in these regions. Overall, the Pharmaceutical Analytical Testing Outsourcing Market showcases a dynamic landscape across different regions, characterized by varying regulatory environments, outsourcing capabilities, and market demands.

Key Players –

Pharmaceutical analytical testing outsourcing companies include Boston Analytical (New Hampshire), West Pharmaceutical Services, Inc. (U.S.), Exova Group PLC (U.K.), Source BioScience (U.K.), Pace Analytical Services, Inc. (U.S.), Merck KGaA (Germany), WuXi AppTec (U.S.), Toxikon (U.S.), Eurofins Scientific (Belgium and Luxembourg), Intertek Group Plc (U.K.), Charles River Laboratories International, Inc (U.S.), SGS SA (U.K.), and Pharmaceutical Product Development, LLC (U.S.).

Related Reports –

Oral Cancer Diagnostics

Automatic Pill Dispenser

Lancet

Medical Oxygen Concentrators

For more information visit at MarketResearchFuture

[industrynewsupdates]

Clinical Trials Procurement Intelligence 2024-2030: What You Need to Know

This clinical trials market is anticipated to grow at a CAGR of 6.49% from 2024 to 2030. North America is the leading region in this category, accounting for over 50.3% of the market share in 2023. This is expected to continue in the forecast period as well, due to several factors, including increased R&D investments and the adoption of new technologies. For example, the use of virtual services in clinical trials is becoming increasingly popular, and this is expected to drive growth in the North American market.

This category is driven by many key factors, including the surge in demand for outsourcing clinical trials, the increasing prevalence of chronic diseases, and the increased investments in R&D by pharmaceutical and biotechnological companies. The outsourcing of this category is becoming increasingly popular, as it allows pharmaceutical companies to focus on their core competencies and to save time and money. The increasing prevalence of chronic diseases is also driving the demand for clinical trials, as there is a need for the development of new and efficient therapeutics to treat these diseases. Also, the increased investments in R&D by pharmaceutical and biotechnological companies are driving the growth of the market, as these companies are constantly developing new drugs and therapies that need to be tested in clinical trials.

This category is a moderately fragmented market due to the presence of numerous players. Strategic alliances between pharmaceutical firms and CROs are anticipated to have a substantial impact on the category’s expansion. Additionally, the swift uptake of new technology for better healthcare contributes to the market's expansion. For instance,

• In November 2022, Calit Health Services (Israel) and IQVIA (US) announced a collaboration to work on clinical trial delivery. The collaboration will combine Calit's extensive clinical trial experience and IQVIA's global reach and expertise in data analytics.

• In April 2022, Charles River Laboratories, a pharmaceutical company that provides preclinical and clinical laboratory services, acquired Explora BioLabs, a provider of contract vivarium research services. This acquisition will allow Charles River to expand its offerings in the cell and gene therapy space.

• In February 2022, Citeline and Norstella merged to form a new company worth $5 billion. Citeline provides clinical trial management software, while Norstella provides clinical trial supplies and services. The merger of these two companies will allow them to offer a more comprehensive suite of services to pharmaceutical companies, which could help speed up the drug development process and improve patient access to new therapies.

Order your copy of the Clinical Trials Procurement Intelligence Report, 2024 - 2030, published by Grand View Research, to get more details regarding day one, quick wins, portfolio analysis, key negotiation strategies of key suppliers, and low-cost/best-cost sourcing analysis

Technological advancements in this category have revolutionized the drug development process by reducing costs and increasing efficiency. With rising trial expenses, failure rates, and a focus on patient-centric trials, the demand for the technology in clinical trials has surged. The landscape of clinical trials is evolving towards decentralization with the utilization of wearables, mHealth, and real-world evidence (RWE). These disruptive technologies enable small, controlled trials and streamline processes from patient enrollment to medication administration and follow-ups through mobile devices. Pharmaceutical companies are investing heavily in AI and big data analytics to leverage their transformative impact on the R&D process, enhance competitiveness, and facilitate company transformation and agility. Additionally, the integration of wearable devices and remote sample collection offers a safer and more convenient experience for participants, potentially increasing patient enrollment and engagement in future studies.

Defining the price and cost of this category is complex as it is dependent on various factors like phase, drug type, and location. Costs range from millions to billions, divided into patient care and research costs. Patient care costs include recruitment, enrollment, medication, safety monitoring, while research costs cover design, implementation, data analysis, and results publication. When budgeting for a clinical trial, consider various cost segments like regulatory, safety, data, quality management, overhead, and site costs. The price of this category is determined by the trial sponsor, typically a pharmaceutical company. Various factors can influence the trial's price, including its scale, complexity, and associated risks. Sponsors take these factors into account when setting the price, as they impact the resources required to conduct a successful trial.

When it comes to sourcing of this category, it is crucial to follow the best practices to ensure the high quality and integrity of the study. These practices include identifying reputable trial sites, evaluating investigator qualifications, prioritizing patient safety, assessing site capabilities, reviewing ethical considerations, evaluating data management systems, monitoring compliance with regulations, conducting site visits and audits. Additionally, it is essential to prioritize suppliers who offer comprehensive documentation, including certificates of analysis and trials conducted. By following these best practices, sponsors can enhance the quality, reliability, and ethical standards of their clinical trials. Finally, considering suppliers who engage in continuous research and development efforts can be beneficial for this category.

Clinical Trials Procurement Intelligence Report scope

• Clinical Trials Category Growth Rate: CAGR of 6.49% from 2024 to 2030

• Pricing Growth Outlook: 2% - 3% (Annually)

• Pricing Models: Unit-based pricing

• Supplier Selection Scope: Cost and pricing, Past engagements, Productivity, Geographical presence

• Supplier selection criteria: Reviewing ethical considerations, prioritizing patient safety, regulatory standards and mandates, category innovations, and others

• Report Coverage: Revenue forecast, supplier ranking, supplier matrix, emerging technology, pricing models, cost structure, competitive landscape, growth factors, trends, engagement, and operating model

Browse through Grand View Research’s collection of procurement intelligence studies:

• Clinical IT Services Procurement Intelligence Report, 2023 - 2030 (Revenue Forecast, Supplier Ranking & Matrix, Emerging Technologies, Pricing Models, Cost Structure, Engagement & Operating Model, Competitive Landscape)

• Clinical Staffing Services Procurement Intelligence Report, 2023 - 2030 (Revenue Forecast, Supplier Ranking & Matrix, Emerging Technologies, Pricing Models, Cost Structure, Engagement & Operating Model, Competitive Landscape)

Key companies profiled

• IQVIA

• PAREXEL International Corporation

• Pharmaceutical Product Development

• Charles River Laboratory

• ICON Plc

• Syneos Health

• Chiltern International Ltd

• Eli Lilly and Company

• Pfizer

• Caidya

Brief about Pipeline by Grand View Research:

A smart and effective supply chain is essential for growth in any organization. Pipeline division at Grand View Research provides detailed insights on every aspect of supply chain, which helps in efficient procurement decisions.

Our services include (not limited to):

• Market Intelligence involving – market size and forecast, growth factors, and driving trends

• Price and Cost Intelligence – pricing models adopted for the category, total cost of ownerships

• Supplier Intelligence – rich insight on supplier landscape, and identifies suppliers who are dominating, emerging, lounging, and specializing

• Sourcing / Procurement Intelligence – best practices followed in the industry, identifying standard KPIs and SLAs, peer analysis, negotiation strategies to be utilized with the suppliers, and best suited countries for sourcing to minimize supply chain disruptions

[poonamcmi]

Pharmaceutical Analytical Testing Market Is Estimated to Witness High Growth Owing to Increasing Emphasis on Test

Pharmaceutical analytical testing involves various activities such as testing of raw materials, packaging components, in-process testing as well as final product testing to ensure quality and safety standards. It helps in determining product identity, strength, quality and purity as well as identifying potential contaminants. Some common analytical testing methods used in pharmaceutical industry include chromatography, spectroscopy, titrimetry and physical tests. It plays a vital role in drug development and production by testing drug substances, excipients as well as final drug products. Increasing regulatory mandates pertaining to safety and efficacy of drugs have further accelerated the need for analytical testing in pharmaceutical industry.

The global pharmaceutical analytical testing market is estimated to be valued at US$ 8.41 Bn in 2024 and is expected to exhibit a CAGR of 8.7% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the pharmaceutical analytical testing are Alibaba Group Holding Limited, Redcentric Plc., Amazon Web Services, Inc., Rackspace Hosting, Inc., Dell EMC, Oracle Corporation, Google LLC, Microsoft Corporation, Hewlett Packard Enterprise Development LP, and International Business Machines Corporation. These major players are focusing on strengthening their presence through mergers and acquisitions as well as launching new testing technologies to enhance their market share.

The Pharmaceutical Analytical Testing Market Size include increasing scope of outsourcing testing activities, growing demand for specialized analytical testing from biopharmaceutical companies and uptake of automated analytical systems. Testing services providers are targeting these opportunities by expanding their geographical presence as well as service portfolio.

Globally, North America dominates the pharmaceutical analytical testing market due to stringent regulatory environment. However, Asia Pacific is expected to witness highest growth owing to increasing investments by international test providers as well as surge in domestic pharmaceutical manufacturing activities. Countries like China and India offer huge potential for outsourced pharmaceutical analytical testing.

Market Drivers Increasing emphasis on test efficiency and quality is a major growth driver for pharmaceutical analytical testing market. Rising need to lower testing costs amid price control regulations has prompted companies to adopt advanced automated analytical techniques and high-throughput systems. Growing complexity of drug molecules also necessitates analytical characterization at each stage of drug development and manufacturing, driving the demand for analytical testing services globally.

PEST Analysis

Political: Pharmaceutical Analytical Testing Market Size And Trends  are regulated by agencies like the US FDA and the EU EMA. Any changes in regulations can impact the type and frequency of testing required.

Economic: Growth in the pharmaceutical industry and increasing drug development activities drive the need for analytical testing services. Changes in the economic conditions can impact R&D spending by pharma companies.

Social: Increase in lifestyle diseases and an aging population are driving the demand for new drugs. This leads to higher need for analytical testing during drug development and manufacturing.

Technological: Adoption of newer tools like artificial intelligence and automation are helping speed up testing processes and data analysis. Technologies like biologics also require specialized analytical characterization techniques.

The Asia Pacific region is one of the largest and fastest growing markets for pharmaceutical analytical testing in terms of value. The Asia Pacific pharmaceutical market has been growing at a high rate led by economies like China, India and South Korea. The presence of major generic drug manufacturers has supported the growth of analytical testing outsourcing in this region.

North America is currently one of the most concentrated markets for pharmaceutical analytical testing globally. It accounts for the highest revenue share due to the large pharmaceutical industry, stringent regulatory requirements as well as the focus on new drug development by major players in the US and Canada. The rising complexity of analytical techniques required also contributes to the high testing expenditures in the region. Get More Insights On, Pharmaceutical Analytical Testing Market About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191